Nanomedicine regulating PSC-mediated intercellular crosstalk: Mechanisms and therapeutic strategies.
10.1016/j.apsb.2024.07.007
- Author:
Hui WANG
1
;
Liang QI
1
;
Han HAN
2
;
Xuena LI
3
;
Mengmeng HAN
2
;
Lei XING
2
;
Ling LI
1
;
Hulin JIANG
2
Author Information
1. Department of Endocrinology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China.
2. State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China.
3. College of Pharmacy, Yanbian University, Yanji 133000, China.
- Publication Type:Review
- Keywords:
Diabetes;
Intercellular crosstalk;
Nanomedicine;
Pancreatic cancer;
Pancreatic fibrosis;
Pancreatic stellate cell;
Pancreatitis;
Therapeutic strategies
- From:
Acta Pharmaceutica Sinica B
2024;14(11):4756-4775
- CountryChina
- Language:English
-
Abstract:
Pancreatic fibrosis (PF) is primarily distinguished by the stimulation of pancreatic stellate cells (PSCs) and excessive extracellular matrix deposition, which is the main barrier impeding drug delivery and distribution. Recently, nanomedicine, with efficient, targeted, and controllable drug release characteristics, has demonstrated enormous advantages in the regression of pancreas fibrotic diseases. Notably, paracrine signals from parenchymal and immune cells such as pancreatic acinar cells, islet cells, pancreatic cancer cells, and immune cells can directly or indirectly modulate PSC differentiation and activation. The intercellular crosstalk between PSCs and these cells has been a critical event involved in fibrogenesis. However, the connections between PSCs and other pancreatic cells during the progression of diseases have yet to be discussed. Herein, we summarize intercellular crosstalk in the activation of PSCs and its contribution to the development of common pancreatic diseases, including pancreatitis, pancreatic cancer, and diabetes. Then, we also examine the latest treatment strategies of nanomedicine and potential targets for PSCs crosstalk in fibrosis, thereby offering innovative insights for the design of antifibrotic nanomedicine. Ultimately, the enhanced understanding of PF will facilitate the development of more precise intervention strategies and foster individually tailored therapeutic approaches for pancreatic diseases.
